Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Hippocampus. 2018 Aug;28(8):586–601. doi: 10.1002/hipo.22962

Figure 1. Reduction of cell proliferation in the DG of GFAP-Tk mice by VGCV.

Figure 1

(A) Experimental timeline of P0–P7 valganciclovir (VGCV) treatment and sacrifice one week after treatment completion in GFAP-Tk+ animals and Tk− controls. (B) The number of CldU+ cells was reduced in Tk+ males and (C) Tk+ females compared to Tk− controls. (D) No difference in the number of Ki67+ cells was detected between Tk− and Tk+ males. (E) The number of Ki67+ cells was reduced in Tk+ versus Tk− females. (F) Experimental timeline of P14–P21 VGCV treatment and sacrifice one week after treatment completion. (G) The number of CldU+ cells was reduced in Tk+ males and (H) females compared to Tk− animals. (I) No difference in the number of Ki67+ cells was detected between Tk− and Tk+ male or (J) female animals. Data are expressed as mean ± SEM. **p<0.01, ***p<0.001